Zepbound Outperforms Wegovy in Weight Loss Trial

By Rene Pretorius

December 6, 2024

The news release from Eli Lilly and Company, titled "Lilly's Zepbound® (tirzepatide) superior to Wegovy® (se...
Strengthening EU Health Competitiveness: MedTech Europe’s Call for Stra...
Boosting Biopharma SMEs in Europe
Urgent Call for Universal Diabetes Care in Europe Amidst Political Apathy
NICE’s Position on AI in Evidence Generation
Diabetes Crisis in Europe: Urgent Public Health and Economic Challenge
Chancellor Announces £50 Million Boost for UK Medicines Manufacturing
Healthcare for Older Adults in Türkiye: A Call for Reform
CHEERS-AI Economic Evaluation
Olympus and Proximie Forge Partnership to Transform Digital Healthcare
Overview of NICE’s Elranatamab Managed Access Agreement
HIQA’s Strategic Blueprint for Health Care Excellence: Draft Corporate ...
NICE Rejects Donanemab for NHS Use Due to Cost Concerns